FDA Actions to Remove Unapproved Drugs from the Market by Drug
Animal-derived thyroid product
Ascorbic acid injection
- FDA notification regarding ascorbic acid injection (October 15, 2019)
Cocaine hydrochloride solution products
- FDA notification regarding cocaine hydrochloride solution products (October 15, 2019)
Dehydrated alcohol
- FDA notification regarding dehydrated alcohol (March 26, 2020)
Iodoquinol Drugs
- Federal Register notice (July 15, 2020)
- FDA Notification Regarding Iodoquinol Drugs (December 5, 2024)
Isometheptene-containing drugs
- Federal Register notice (January 10, 2014)
- FDA notification regarding isometheptene-containing drug products (June 13, 2018)
Isoxsuprine
- Federal Register notice (July 15, 2020)
- FDA Notification Regarding Isoxsuprine Hydrochloride Drug Products (November 3, 2021)
Local anesthetics
- FDA notification regarding unapproved local anesthetics and required methemoglobinemia warning (October 22, 2018)
Meperidine hydrochloride and promethazine hydrochloride drugs
- Federal Register notice (November 16, 2017)
- FDA notification regarding meperidine hydrochloride and promethazine hydrochloride drug products (April 2, 2018)
Nonsteroidal anti-inflammatory drugs (NSAIDs)
- FDA notification regarding unapproved choline magnesium trisalicylate (August 26, 2022)
- FDA notification regarding unapproved salsalate (August 26, 2022)
Otic drugs
- Federal Register notice: Unapproved and misbranded otic prescription drug products; Enforcement action dates (July 2, 2015)
Potassium phosphates injection
- FDA notification regarding potassium phosphates injection (August 1, 2024)
Tetracaine ophthalmic solution